Anthera Pharmaceuticals Welcomes Georgina Kilfoil as Senior Vice President of Product Development and Clinical Operations

HAYWARD, Calif., March 23 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has hired Georgina Kilfoil to the newly created position of Senior Vice President of Product Development and Clinical Operations.  

"Georgina brings over 18 years of project management and clinical research experience, making her a valuable and welcome addition to our senior management team," stated Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals.  "Her expertise in developing and managing programs for inflammatory diseases will be beneficial to Anthera and our three product candidates."

Prior to joining Anthera, Ms. Kilfoil was a project management consultant with InClin, Inc., providing strategic development advice to pharmaceutical and biotechnology companies.  Prior to InClin, Ms. Kilfoil served as Vice President of Alliances and Project Management at Peninsula Pharmaceuticals, where she played a key role in the development and successful NDA filing of Doribax®.  Ms. Kilfoil has a Bachelor of Science Degree in Pharmacology from the University of Bristol, United Kingdom, and a Masters of Business Administration from the Australian Graduate School of Management, Sydney, Australia.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. Anthera has worldwide rights to its product candidates, with the exception of Japan, where Shionogi & Co., Ltd. retains commercial rights to its sPLA2 product candidates.

CONTACT: Juliane Snowden of Burns McClellan, Inc., [email protected] of 212.213.0006.

SOURCE Anthera Pharmaceuticals, Inc.